Drugs / ARC-02
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07691606 | Jun 2026 → Jan 2029 expected | B-cell non-Hodgkin lymphoma | Taiho Oncology, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARC-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07691606 ↗ |
| Route | Intravenous | “Intravenous (IV) infusion.” NCT07691606 ↗ |